ADMA Biologics Statistics

Total Valuation

ADMA Biologics has a market cap or net worth of $4.70 billion. The enterprise value is $4.71 billion.

Market Cap	4.70B
Enterprise Value	4.71B

Important Dates

The last earnings date was Wednesday, May 7, 2025, after market close.

Earnings Date	May 7, 2025
Ex-Dividend Date	n/a

Share Statistics

ADMA Biologics has 238.73 million shares outstanding. The number of shares has increased by 8.72% in one year.

Current Share Class	238.73M
Shares Outstanding	238.73M
Shares Change (YoY)	+8.72%
Shares Change (QoQ)	-0.50%
Owned by Insiders (%)	1.88%
Owned by Institutions (%)	86.96%
Float	234.14M

Valuation Ratios

The trailing PE ratio is 23.56 and the forward PE ratio is 25.46.

PE Ratio	23.56
Forward PE	25.46
PS Ratio	10.09
Forward PS	12.27
PB Ratio	12.58
P/TBV Ratio	12.72
P/FCF Ratio	51.86
P/OCF Ratio	46.44
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 29.45, with an EV/FCF ratio of 51.98.

EV / Earnings	22.78
EV / Sales	10.26
EV / EBITDA	29.45
EV / EBIT	30.99
EV / FCF	51.98

Financial Position

The company has a current ratio of 6.58, with a Debt / Equity ratio of 0.22.

Current Ratio	6.58
Quick Ratio	3.20
Debt / Equity	0.22
Debt / EBITDA	0.51
Debt / FCF	0.90
Interest Coverage	12.53

Financial Efficiency

Return on equity (ROE) is 78.45% and return on invested capital (ROIC) is 25.32%.

Return on Equity (ROE)	78.45%
Return on Assets (ROA)	22.06%
Return on Invested Capital (ROIC)	25.32%
Return on Capital Employed (ROCE)	33.26%
Revenue Per Employee	$670,629
Profits Per Employee	$301,855
Employee Count	685
Asset Turnover	1.07
Inventory Turnover	1.25

Taxes

Income Tax	-66.01M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +116.37% in the last 52 weeks. The beta is 0.57, so ADMA Biologics's price volatility has been lower than the market average.

Beta (5Y)	0.57
52-Week Price Change	+116.37%
50-Day Moving Average	20.34
200-Day Moving Average	18.32
Relative Strength Index (RSI)	43.27
Average Volume (20 Days)	4,290,271

Short Selling Information

The latest short interest is 12.35 million, so 5.17% of the outstanding shares have been sold short.

Short Interest	12.35M
Short Previous Month	13.26M
Short % of Shares Out	5.17%
Short % of Float	5.27%
Short Ratio (days to cover)	3.09

Income Statement

In the last 12 months, ADMA Biologics had revenue of $459.38 million and earned $206.77 million in profits. Earnings per share was $0.84.

Revenue	459.38M
Gross Profit	241.54M
Operating Income	152.04M
Pretax Income	n/a
Net Income	206.77M
EBITDA	159.94M
EBIT	152.04M
Earnings Per Share (EPS)	$0.84

Full Income Statement

Balance Sheet

The company has $71.63 million in cash and $82.01 million in debt, giving a net cash position of -$10.39 million or -$0.04 per share.

Cash & Cash Equivalents	71.63M
Total Debt	82.01M
Net Cash	-10.39M
Net Cash Per Share	-$0.04
Equity (Book Value)	373.42M
Book Value Per Share	1.57
Working Capital	298.32M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $101.22 million and capital expenditures -$10.58 million, giving a free cash flow of $90.64 million.

Operating Cash Flow	101.22M
Capital Expenditures	-10.58M
Free Cash Flow	90.64M
FCF Per Share	$0.38

Full Cash Flow Statement

Margins

Gross margin is 52.58%, with operating and profit margins of 33.10% and 45.01%.

Gross Margin	52.58%
Operating Margin	33.10%
Pretax Margin	30.64%
Profit Margin	45.01%
EBITDA Margin	34.82%
EBIT Margin	33.10%
FCF Margin	19.73%

Dividends & Yields

ADMA Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.72%
Shareholder Yield	n/a
Earnings Yield	4.40%
FCF Yield	1.93%

Analyst Forecast

The average price target for ADMA Biologics is $24.25, which is 23.16% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$24.25
Price Target Difference	23.16%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	19.77%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ADMA Biologics has an Altman Z-Score of 17.19 and a Piotroski F-Score of 7.

Altman Z-Score	17.19
Piotroski F-Score	7